ArticleSignal transduction and targeted therapy2026

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.

Zekai Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.